AIM: To evaluate the population effectiveness of stop-smoking medications while accounting for potential recall bias by controlling for quit attempt recency. DESIGN: Prospective cohort survey. SETTING: United Kingdom, Canada, Australia and the United States. PARTICIPANTS: A total of 7436 adult smokers (18+ years) selected via random digit dialling and interviewed as part of the International Tobacco Control Four Country Survey (ITC-4) between 2002 and 2009. Primary analyses utilized the subset of respondents who participated in 2006 or later (n = 2550). MEASUREMENTS: Continuous abstinence from smoking for 1 month/6 months. FINDINGS: Among participants who recalled making a quit attempt within 1 month of interview, those who reported using varenicline, bupropion or nicotine patch were more likely to maintain 6-month continuous abstinence from smoking compared to those who attempted to quit without medication [adjusted odds ratio (OR) 5.84, 95% confidence interval (CI) (2.12-16.12), 3.94 (0.87-17.80), 4.09 (1.72-9.74), respectively]; there were no clear effects for oral NRT use. Those who did not use any medication when attempting to quit tended to be younger, to be racial/ethnic minorities, to have lower incomes and to believe that medications do not make quitting easier. CONCLUSIONS: Consistent with evidence from randomized controlled trials, smokers in the United Kingdom, Canada, Australia and the United States are more likely to succeed in quit attempts if they use varenicline, bupropion or nicotine patch. Previous population studies that failed to find an effect failed to control adequately for important sources of bias. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
AIM: To evaluate the population effectiveness of stop-smoking medications while accounting for potential recall bias by controlling for quit attempt recency. DESIGN: Prospective cohort survey. SETTING: United Kingdom, Canada, Australia and the United States. PARTICIPANTS: A total of 7436 adult smokers (18+ years) selected via random digit dialling and interviewed as part of the International Tobacco Control Four Country Survey (ITC-4) between 2002 and 2009. Primary analyses utilized the subset of respondents who participated in 2006 or later (n = 2550). MEASUREMENTS: Continuous abstinence from smoking for 1 month/6 months. FINDINGS: Among participants who recalled making a quit attempt within 1 month of interview, those who reported using varenicline, bupropion or nicotine patch were more likely to maintain 6-month continuous abstinence from smoking compared to those who attempted to quit without medication [adjusted odds ratio (OR) 5.84, 95% confidence interval (CI) (2.12-16.12), 3.94 (0.87-17.80), 4.09 (1.72-9.74), respectively]; there were no clear effects for oral NRT use. Those who did not use any medication when attempting to quit tended to be younger, to be racial/ethnic minorities, to have lower incomes and to believe that medications do not make quitting easier. CONCLUSIONS: Consistent with evidence from randomized controlled trials, smokers in the United Kingdom, Canada, Australia and the United States are more likely to succeed in quit attempts if they use varenicline, bupropion or nicotine patch. Previous population studies that failed to find an effect failed to control adequately for important sources of bias. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: M E Thompson; G T Fong; D Hammond; C Boudreau; P Driezen; A Hyland; R Borland; K M Cummings; G B Hastings; M Siahpush; A M Mackintosh; F L Laux Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: G T Fong; K M Cummings; R Borland; G Hastings; A Hyland; G A Giovino; D Hammond; M E Thompson Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: David B Buller; Abigail Halperin; Herbert H Severson; Ron Borland; Michael D Slater; Erwin P Bettinghaus; David Tinkelman; Gary R Cutter; William Gill Woodall Journal: J Public Health Manag Pract Date: 2014 Mar-Apr
Authors: Bryan W Heckman; K Michael Cummings; Karin A Kasza; Ron Borland; Jessica L Burris; Geoffrey T Fong; Ann McNeill; Matthew J Carpenter Journal: Am J Prev Med Date: 2017-03-20 Impact factor: 5.043
Authors: Karin A Kasza; K Michael Cummings; Matthew J Carpenter; Monica E Cornelius; Andrew J Hyland; Geoffrey T Fong Journal: Addiction Date: 2014-11-20 Impact factor: 6.526
Authors: Philip H Smith; Karin A Kasza; Andrew Hyland; Geoffrey T Fong; Ron Borland; Kathleen Brady; Matthew J Carpenter; Karen Hartwell; K Michael Cummings; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-04 Impact factor: 4.244